CytomX Therapeutics (CTMX) Receivables - Other (2015 - 2026)

CytomX Therapeutics (CTMX) has 6 years of Receivables - Other data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Receivables - Other changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $500000.0, up 2172.73% from the prior year.
• Receivables - Other rose to $1.5 million in Q1 2026, from $500000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.5 million in Q1 2026 to a low of $22000.0 in Q4 2024.
• A 3-year average of $674000.0 and a median of $500000.0 in 2025 frame the typical range for Receivables - Other.
• The widest YoY moves for Receivables - Other: up 2172.73% in 2025, down 2172.73% in 2025.
• Tracing CTMX's Receivables - Other over 3 years: stood at $22000.0 in 2024, then soared by 2172.73% to $500000.0 in 2025, then surged by 200.0% to $1.5 million in 2026.
• The last three Receivables - Other figures came in at $1.5 million (Q1 2026), $500000.0 (Q4 2025), and $22000.0 (Q4 2024), per Business Quant data.